Palatin Technologies 8-K 2008
Registrant's telephone number, including area code: (609) 495-2200
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
Item 1.01 Entry into a Material Definitive Agreement.
On June 27, 2008, we entered into an amendment (the Amendment) to the Research Collaboration and License Agreement dated January 30, 2007 between AstraZeneca AB and us (the Agreement). The Agreement was previously filed as Exhibit 10.2 of our quarterly report on Form 10-Q for the quarter ended December 31, 2006, filed with the SEC on February 8, 2007. Under the Amendment, we have granted AstraZeneca the right to license certain additional compounds, patents and patent applications for use in treatment of obesity, diabetes and related metabolic syndrome, and AstraZeneca has agreed to pay milestone payments thereon contingent upon development, regulatory and sales milestones, together with royalties on sale of approved products.
Item 8.01 Other Events.
On July 1, 2008, we issued a press release, attached hereto as Exhibit 99 and made part of this report, announcing the Amendment.
Item 9.01 Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.